bioRxivCancer BiologyPreprint
Curvature Analysis of Estrogen Receptor Positive Breast Cancer Under PI3K Inhibition
Romeil Sandhu, Eneda Toska, Maurizio Scaltriti, José Baselga, Joseph Deasy, Jung Hun Oh, Sarah Tannenbaum, Allen Tannenbaum
Abstract
In this note, we re-examine the work of Bosch et al. from a network point of view. In particular, we employ an extended defintion of Ollivier-Ricci curvature that allows us to study graphs with both positive and negative weights. This is done by utilizing a dual formulation of the Wasserstein 1-metric, allowing us to extend the Earth Movers Distance to signed measures. The resulting curvature may be applied study the robustness properties of general networks modelled as weighted graphs. In this note, we apply the theory to elucidate the robustness and therefore possible mechanisms of resistance of estrogen receptor positive breast cancer under PI3K inhibition.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer
J. Gomez Tejeda Zanudo, R. Albert·bioRxiv·Oct 27, 2017
- Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations
J. Gomez Tejeda Zanudo, P. Mao, … N. Wagle·bioRxiv·Aug 25, 2020
- PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance
Han Wang, Zixi Yun, … Hung‐Ying Kao·bioRxiv·May 15, 2025
- WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancer
Wei He, Diane M. Demas, … William T. Baumann·npj Systems Biology and ApplicationsPeer-reviewed·Nov 17, 2025
- Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer
Michael W. Lero, Jennifer S. Morgan, … Leslie M. J. Shaw·Journal of Biological ChemistryPeer-reviewed·Aug 10, 2026
- PELP1/SRC-3-dependent regulation of metabolic kinases drives therapy resistant ER+ breast cancer
T. H. Truong, E. A. Benner, … J. H. Ostrander·bioRxiv·Aug 7, 2020